- Home
- MLYS vs DIN Comparison
MLYS vs DIN Comparison
Compare MLYS & DIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- DIN
- Stock Information
- Founded
- MLYS 2019
- DIN 1958
- Country
- MLYS United States
- DIN United States
- Employees
- MLYS N/A
- DIN N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- DIN Restaurants
- Sector
- MLYS Health Care
- DIN Consumer Discretionary
- Exchange
- MLYS Nasdaq
- DIN Nasdaq
- Market Cap
- MLYS 590.3M
- DIN 488.3M
- IPO Year
- MLYS 2023
- DIN 1991
- Fundamental
- Price
- MLYS $13.88
- DIN $32.73
- Analyst Decision
- MLYS Strong Buy
- DIN Buy
- Analyst Count
- MLYS 2
- DIN 7
- Target Price
- MLYS $30.00
- DIN $43.00
- AVG Volume (30 Days)
- MLYS 122.0K
- DIN 867.2K
- Earning Date
- MLYS 11-05-2024
- DIN 10-30-2024
- Dividend Yield
- MLYS N/A
- DIN 6.15%
- EPS Growth
- MLYS N/A
- DIN 20.35
- EPS
- MLYS N/A
- DIN 5.96
- Revenue
- MLYS N/A
- DIN $821,388,000.00
- Revenue This Year
- MLYS N/A
- DIN N/A
- Revenue Next Year
- MLYS N/A
- DIN $1.24
- P/E Ratio
- MLYS N/A
- DIN $5.57
- Revenue Growth
- MLYS N/A
- DIN N/A
- 52 Week Low
- MLYS $5.85
- DIN $28.25
- 52 Week High
- MLYS $16.91
- DIN $53.26
- Technical
- Relative Strength Index (RSI)
- MLYS 70.82
- DIN 55.28
- Support Level
- MLYS $11.73
- DIN $31.00
- Resistance Level
- MLYS $12.27
- DIN $35.76
- Average True Range (ATR)
- MLYS 0.61
- DIN 1.22
- MACD
- MLYS 0.19
- DIN 0.46
- Stochastic Oscillator
- MLYS 98.50
- DIN 53.74
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About DIN Dine Brands Global Inc.
Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations, and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.